Core Viewpoint - 康哲药业's stock rose over 4% following the approval of its innovative oral small molecule JAK1 inhibitor, Povorcitinib, to commence clinical trials for treating non-segmental vitiligo and moderate to severe hidradenitis suppurativa [1] Group 1: Company Developments - 康哲药业's subsidiary, 德镁医药有限公司, received a clinical trial approval notice from the National Medical Products Administration (NMPA) of China on August 27, 2025, and officially received the notice on August 28, 2025 [1] - The approved clinical trials for Povorcitinib will focus on non-segmental vitiligo and moderate to severe hidradenitis suppurativa [1] Group 2: Product Information - Povorcitinib is a selective oral small molecule JAK1 inhibitor, which holds substance and use patents in specific countries/regions [1] - Currently, Povorcitinib is undergoing Phase 3 clinical trials for non-segmental vitiligo, hidradenitis suppurativa, and nodular prurigo in several overseas countries, along with Phase 2 trials for asthma and chronic spontaneous urticaria [1]
港股异动 | 康哲药业(00867)午前涨超4% 创新药口服小分子JAK1抑制剂Povorcitinib获批准开展临床试验